Status:
COMPLETED
Long Term Arrhythmia Risk and Cardiovascular Events in Hematopoietic Stem Cell Transplant
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Collaborating Sponsors:
Medtronic
Conditions:
Hematopoietic Stem Cell Transplant
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to better understand the following aims: 1. Aim 1: To evaluate the rate of recurrent Atrial Fibrillation (AF)/Atrial Flutter (AFL) in hematopoietic stem call transplant (...
Detailed Description
We propose a registry study in hematopoietic stem cell transplant (HSCT) patients with incident atrial fibrillation/atrial flutter (AF/AFL) during the initial 30 days of transplant who will be implant...
Eligibility Criteria
Inclusion
- Age ≥18
- CHADS-VASc ≥ 2
- Recovery of platelets to \>50,000 within 90 days of incident atrial fibrillation (AF) diagnosis
- Discharge from the incident stem cell transplant (SCT) hospitalization
- Normal sinus rhythm at the time of consent
Exclusion
- Prior history of atrial fibrillation (AF) or atrial flutter
- CHADS-VASc \<2
- Platelets \<50,000 after 90 days post transplantation
- Continued SCT hospitalization at 90 days
- Inability to receive anticoagulation
- AF or other arrhythmia at the time of consent
- Current use of a class IC or III antiarrhythmic medication
- Inability to provide informed consent/significant cognitive impairment
- Expected survival less than one year.
Key Trial Info
Start Date :
April 21 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 17 2024
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT04118530
Start Date
April 21 2021
End Date
June 17 2024
Last Update
October 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104